Early Clinical Development: Phase 1 to Proof-of-Concept Studies

Selecting the right molecules for development - Quickly identify the best drug candidates. Knowing what it takes to develop a successful drug, we help clients select the best molecules for development. Our unique integration of scientific capabilities enables us to provide a complete assessment of molecule...

Our streamlined approach to developing drug substance has been shown to reduce manufacturing costs by 50% from preclinical to Phase I. To best support our customer's needs, we have made significant investments in technologies and equipment to meet the increasing demand for complex small-scale drug substanc...

Creating patient-centric formulations and scaling up from pilot-scale to commercial manufacturing, we help clients turn promising molecules into successful drug products. Quotient Sciences specialize in flexible drug manufacturing strategies to not just scale up your drug product to its registration a...

35+ years developing a breadth of formulations across a range of indications, with services that include:

- Formulation design 
- Pre-formulation screening
- First-in-human
- Solubility enhancement 
- Modified release
- Analytical Services 
- Process optimization &am...

Quotient Sciences offer comprehensive clinical pharmacology services for exploratory and regulatory-driven studies. Our end-to-end services encompass expert clinical study design, thorough data analysis, and detailed reporting. With our fully integrated approach, we ensure seamless clinical program ex...

We understand on-study changes to early phase study designs and dosing are frequent and so our study strategy for study database design and reporting is built around flexibility and rapid implementation. Data sciences services are fully integrated within a project, with in-house data scientist special...

We can help design and develop your packaging, labelling and distribution strategy for Phase I, Phase II and Phase III clinical studies, so you’ll no longer have to worry about the challenge of getting your drug product to multiple sites in time for clinical trials.

The development of acceptable, palatable pediatric formulations is a key feature within the industry today, driven by patient needs and regulatory requirements. Quotient Sciences has extensive knowledge and capabilities that enable us to provide you with a unique integrated pediatric development solution.

Accelerating orphan drug development from candidate selection to commercial manufacture and supply.

- Integrated capabilities and expertise- Pre-formulation and API characterisation
- Formulation and process development
- First-in-human clinical testing and acceleration into POC trials
- Be...

Translational Pharmaceutics® accelerates drug development by integrating formulation development, real-time manufacturing and clinical testing. The platform is unique to Quotient Sciences and has been used over the last decade by global pharmaceutical and biotech companies across over 400 drug programs. qq...

In 2026 we are continuing with the Day in the Life Of series, where we interview the people behind the medicines and find out what drives them, and how they go to where they are today. The series gives a personal insight into what it's like to work in the pharmaceutical industry and contribute to patients' health. 

Dedicated to adaptive early phase clinical trials and drug development, Quotient Sciences can help accelerate your molecule from first-in-human (FIH) to proof of concept (POC). We are focused on delivering the insight you need to design and deliver your clinical pharmacology program with confidence. Our fully integrated approach ensures seamless execution and high-quality results—delivered safely and rapidly

Quotient Sciences, a leading global drug development and manufacturing accelerator, and UK technology innovation centre, CPI, have signed a memorandum of understanding (MoU) to form a Joint Venture (JV) aimed at accelerating the development of RNA-based therapies.

Achieve your molecule’s next milestone with fit-forphase drug product formulations, backed by trusted data and the expertise you need to navigate the increasing complexity of small molecule and synthetic peptide therapeutics. Our adaptive approach assures scalable solutions for your molecule’s development—from preclinical through commercial drug product formulation, manufacturing, and supply.

Quotient Sciences Featured as part of MMV Annual Report

Translational Pharmaceutics® is a disruptive approach to drug development that helps you forge your own path to success and optimize every step by redefining the complementary, interconnected relationship between drug product design, supply and clinical testing. The Quotient Sciences Translational Pharmaceutics® platform integrates activities and adapts solutions to help you reach key milestones as quickly and efficiently as possible. A

Senior Director of Product Development, Robert Cornog, and Senior Director of Integrated Development, Brad Rowe, recently contributed to Contract Pharma's feature on HPAPI outsourcing, "Why HPAPI Outsourcing Is Surging", explaining the evolving demand, regulatory shifts, and analytical challenges shaping the HPAPI contract manufacturing market.

As a leading provider of human ADME studies, we have the scientific expertise and operational know-how to design and deliver human ADME programs in preparation for NDA, MAA and global regulatory filings. 

After another successful year of bringing the pharmaceutical community together at CPHI Milan in October, hear direct from the exhibitors on why the event is so important for them and the industry as a whole. 

With decades of experience in developing palatable pediatric and patient-centric formulations, Quotient Sciences is actively engaged in the development of pediatric products on behalf of pharmaceutical and biotech customers.

Our innovative approach to formulation development is based on our proven track record in early clinical evaluation delivering phase-appropriate formulations across the product development pathway from preclinical to late-stage. With expertise in simple and complex dosage forms, our approach has been validated through our work with over 1,500 molecules at all stages of drug development.

At Quotient Sciences, we recognize that careful selection of appropriate delivery technologies is key to the design of successful MR formulations. We have extensive experience in using a wide variety of formulation technologies, having supported hundreds of modified-release formulations over the last three decades. Coupled with our agile and flexible approach to clinical and commercial manufacturing, this makes us the ideal partner to provide an end-to-end solution for the development of MR drug products.

Our Translational Pharmaceutics® approach enables First-in-Human studies by re-engineering the transition of your drug molecule into clinical development and shortening the timeline to Proof-of-Concept.

Quotient Sciences specialize in guiding drug products through the critical transition from late-stage optimization and registration batch manufacturing through to full commercial readiness. Our approach is built on rigorous science, regulatory alignment, risk-based focus, and operational flexibility.